The European Medicines Agency (EMA) has partially approved Leqembi (lecanemab) for patients with mild cognitive decline or mild dementia due to Alzheimer’s disease, reversing a prior rejection. The treatment is now authorized for those with a lower risk of adverse side effects, specifically individuals with one or no copies of the ApoE4 gene. The EMA had initially declined the application, citing concerns about potential side effects, including brain hemorrhaging. The approval allows Leqembi to be administered under a controlled access program, requiring monitoring to mitigate risks.